DelveInsight’s, Aneurysmal Subarachnoid Hemorrhage (ASH) – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Aneurysmal Subarachnoid Hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Aneurysmal Subarachnoid Hemorrhage Understanding
Aneurysmal Subarachnoid Hemorrhage (ASH): Overview
Subarachnoid hemorrhage (SAH) is a life-threatening type of stroke caused by bleeding into the space surrounding the brain. Aneurysmal Subarachnoid Hemorrhage can be caused by a ruptured aneurysm, AVM, or head injury. One-third of patients will survive with good recovery; one-third will survive with a disability; and one-third will die. The subarachnoid space is the area between the brain and the skull. It is filled with cerebrospinal fluid (CSF), which acts as a floating cushion to protect the brain. When blood is released into the subarachnoid space, it irritates the lining of the brain, increases pressure on the brain, and damages brain cells. At the same time, the area of brain that previously received oxygen-rich blood from the affected artery is now deprived of blood, resulting in a stroke. Aneurysmal Subarachnoid Hemorrhage is frequently a sign of a ruptured aneurysm.
Symptoms
• Sudden onset of a severe headache (often described as "the worst headache of my life")
• nausea and vomiting
• stiff neck
• sensitivity to light (photophobia)
• blurred or double vision
• loss of consciousness
• seizures
Diagnosis
When a person is brought to the emergency room with a suspected brain hemorrhage, doctors will learn as much as possible about his or her symptoms, current and previous medical problems, medications, and family history. The person's condition is assessed quickly. Diagnostic tests will help determine the source of the bleeding.
• Computed Tomography (CT)
• Lumbar puncture
• Angiogram
• Magnetic resonance imaging (MRI) scan
Treatment
Treatment for Subarachnoid hemorrhage varies, depending on the underlying cause of the bleeding and the extent of damage to the brain. Treatment may include lifesaving measures, symptom relief, repair of the bleeding vessel, and complication prevention.
Medication: Pain medication will be given to alleviate headache, and anticonvulsant medication may be given to prevent or treat seizures.
Surgery: If the Subarachnoid hemorrhage is from a ruptured aneurysm, surgery may be performed to stop the bleeding. Options include surgical clipping or endovascular coiling.
If the Subarachnoid hemorrhage is from a bleeding arteriovenous malformation, surgery may be performed to remove the arteriovenous malformation.
Aneurysmal Subarachnoid Hemorrhage Emerging Drugs Chapters
This segment of the Aneurysmal Subarachnoid Hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aneurysmal Subarachnoid Hemorrhage Emerging Drugs
• Nicardipine implant: BIT pharma
NicaPlant is a nicardipine modified-release formulation. It is presented in the form of a rod-shaped implant with a 4 mg nicardipine load. Following aneurysm clip ligation, NicaPlant implants will be placed into the basal cisterns in direct contact with the exposed cerebral blood vessel walls. This study of NicaPlant is conducted in patients who have a subarachnoid haemorrhage. Patients will be randomized in two treatment groups. Both groups will receive the standard of care and the investigational group will receive in addition NicaPlant. NicaPlant is tested to reduce the long-term complications of aneurysmal subarachnoid haemorrhage (aSAH).

Further product details are provided in the report……..
Aneurysmal Subarachnoid Hemorrhage: Therapeutic Assessment
This segment of the report provides insights about the different Aneurysmal Subarachnoid Hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Aneurysmal Subarachnoid Hemorrhage
There are approx. 10+ key companies which are developing the therapies for Aneurysmal Subarachnoid Hemorrhage. The companies which have their Aneurysmal Subarachnoid Hemorrhage drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Idorsia Pharmaceuticals Ltd., BIT Pharma etc.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Aneurysmal Subarachnoid Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Oral
• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as
• Small molecules
• Proteins and peptides

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aneurysmal Subarachnoid Hemorrhage: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Aneurysmal Subarachnoid Hemorrhage therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aneurysmal Subarachnoid Hemorrhage drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Aneurysmal Subarachnoid Hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Aneurysmal Subarachnoid Hemorrhage.
• September 2020: Minnetronix Medical is currently evaluating the safety and effectiveness of its Neurapheresis system – an extracorporeal system and catheter for removing red blood cells and ruptured blood byproducts from hemorrhagic cerebrospinal fluid following aneurysmal subarachnoid hemorrhage. It completed a feasibility study of the Neurapheresis Cerebrospinal Fluid (CSF) Treatment Platform in 2018. The 30-patient, interventional PILLAR-XT IDE clinical trial is an extension of that study and is slated for completed next spring. If successful, it would support FDA approval of the Neurapheresis CSF platform.
Aneurysmal Subarachnoid Hemorrhage Report Insights
• Aneurysmal Subarachnoid Hemorrhage Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Aneurysmal Subarachnoid Hemorrhage Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Aneurysmal Subarachnoid Hemorrhage drugs?
• How many Aneurysmal Subarachnoid Hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aneurysmal Subarachnoid Hemorrhage?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aneurysmal Subarachnoid Hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aneurysmal Subarachnoid Hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Idorsia Pharmaceuticals Ltd.
• BIT Pharma GmbH
• Lumos Labs, Inc.
• Minnetronix
Key Products
• Clazosentan
• Nicardipine (Nicardipine implant)